IRCT20230415057911N2 IRCT 2024-03-16 Iran University of Medical Sciences Efficacy of Lacosamide and Topiramate on Control of Neonatal Refractory Seizures Comparison of the Safety and Efficacy of Lacosamide and Topiramate on Control of Neonatal Refractory Seizures 2023-03-01 anticipated 54 Complete https://irct.ir/trial/74891 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The block randomization with block size of 4 and 6 used.generation of random sequence was done using www.sealedenvelope.com website. The the random list were provided to a epidemiologist who had no involvement to selection drug. Then subjects were randomly assigned into two groups of Locasamaid and Topiramate. 3 Neonatal Seizure. Intervention 1: Intervention group 1: Infants receive Lacosamide tablets (manufactured by Dr. Abidi Company, Iran) twice a day at a dosage of 2 mg/kg/day, If no treatment response, 2 mg/kg is added to the previous dosage every 48 hours until the dose reaches 12 mg/kg, and if a neonate does not respond to the treatment within 48 hours after receiving dosage of 12 mg/kg, the drug is stopped. Intervention 2: Intervention group 2: Infants receive Topiramate tablets (manufactured by Aria Company, Iran) twice a day at a dose of 5 mg/kg/day. If no treatment response, 1 mg/kg is added to the previous dosage every 48 hours until we reach to dosage of 10 mg/kg, and if a neonate does not respond to the treatment until 48 hours after receiving the dose of 10 mg/kg, the drug is stopped. . Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information